Clinical trials: CDM

Congenital Myotonic Dystrophy

Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy

• Completed
• Age: 6 to 16 years
• Phase 2/3
• Results posted

This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2/3 study of patients (aged 6 to 16 years) diagnosed with Congenital Myotonic Dystrophy (Congenital DM1).

Trial name

NCT03692312

Testing

Tideglusib

Where

14 sites in United States, Australia and 3 more

Volunteers

56 people

Sponsor

AMO Pharma Limited